arrow
E

Emily Symington

barts health nhs trust
H指数:15
被引数:2,023

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results

重度A型血友病患者接受valoctocogene roxaparvovec基因转移后5年的疗效、安全性和生活质量持久性:GENEr8-1 III期试验最终结果

2026-04-010
OAAI
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial

在3期GENEr8-1试验中,valoctocogenene roxaparvovec基因转移治疗严重血友病A后4年的疗效,安全性和生活质量

2024-11-010
OAAI
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
2023-02-23146
OA
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
2023-02-23107
OA